Latest News and Press Releases

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...

Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11,...

Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS Two abstracts selected for oral presentations at American Society of Hematology Annual Meeting,...

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...

CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...

Initial clinical data showing anti-tumor activity with ALRN-6924 presented at ASCO 2017 -Presentation selected for Best of ASCO Meetings Ongoing enrollment of clinical trials in PTCL and AML/MDS ...

CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...

CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for...

Company to Advance Pipeline of Clinical Candidates Based on its Innovative Stapled Peptide Platform Funding Accelerates Lead Oncology Program, ALRN-6924, a First-in-Class Dual Inhibitor of...